HA

Mythics, LLC. Recognized as Oracle Linux Partner of the Year for 2023

Retrieved on: 
Thursday, November 9, 2023
Linux, Oracle Linux, OPN, Virtualization, HA, The Mythical Man-Month, Software, Digital transformation, Senior, Public sector, Ansible, Oracle, BlackBerry PlayBook, Asset management, Sales

VIRGINIA BEACH, Va., Nov. 9, 2023 /PRNewswire/ -- Mythics, LLC has been named the 2023 Oracle Linux and Virtualization North America Partner of the Year.

Key Points: 
  • VIRGINIA BEACH, Va., Nov. 9, 2023 /PRNewswire/ -- Mythics, LLC has been named the 2023 Oracle Linux and Virtualization North America Partner of the Year.
  • This recognition was apart of the annual Oracle Linux Partner Summit for North America, which aims to acknowledge and honor partners for continued efforts to solve customer's business challenges.
  • Mythics, LLC has been named the 2023 Oracle Linux and Virtualization North America Partner of the Year.
  • "We are thrilled to be recognized as the 2023 Oracle Linux and Virtualization North America Partner of the Year," said Sloan Frey, Senior Vice President of Sales for Mythics.

Integral Molecular Launches TiterSafe™ Influenza Virus-Like Particles for Safe and Convenient Vaccine Testing

Retrieved on: 
Tuesday, November 7, 2023
FDA, Neuraminidase, HA, SARS-CoV-2, RNA, Architecture, Infection, Research, Virus, Biodegradable additives, NA, Serum, Path integral molecular dynamics, Influenza, Fever Dream, DNA, Vaccine, Zika fever

PHILADELPHIA, Nov. 7, 2023 /PRNewswire/ -- Integral Molecular, a leading provider of reagents for vaccine evaluation, announces the launch of TiterSafe™ influenza virus-like particles , an off-the-shelf virus-alternative for key experiments in testing influenza vaccines.

Key Points: 
  • PHILADELPHIA, Nov. 7, 2023 /PRNewswire/ -- Integral Molecular, a leading provider of reagents for vaccine evaluation, announces the launch of TiterSafe™ influenza virus-like particles , an off-the-shelf virus-alternative for key experiments in testing influenza vaccines.
  • In contrast, traditional assays require the difficult preparation of live influenza virus, potentially expose researchers to infection, and need dedicated containment facilities for pandemic virus strains.
  • TiterSafe particles mimic the architecture of live virus, featuring surface influenza proteins hemagglutinin (HA) and neuraminidase (NA) along with an interior protein core.
  • Inhibition of this clumping by anti-HA antibodies in serum (an "HAI assay") is the standard FDA-accepted method for influenza vaccine assessment.

Bioplastics Market is to grow by USD 114.24 billion from 2022 to 2027- Technavio

Retrieved on: 
Tuesday, October 24, 2023
DuPont, Car, Horticulture, HA, Braskem, Biopolymer, Carbon, Exxon Mobil Corp. v. Saudi Basic Industries Corp., Evonik Industries, Geography, BASF, CG, Growth, BASF SE, Solvay S.A., SE, USD, Plastic, Agriculture, Corbion, Thermoplastic, Speciality chemicals

NEW YORK, Oct. 23, 2023 /PRNewswire/ -- The bioplastics market is expected to grow by USD 114.24 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Oct. 23, 2023 /PRNewswire/ -- The bioplastics market is expected to grow by USD 114.24 billion from 2022 to 2027.
  • In addition, the growth momentum of the market will progress at a CAGR of 27.53% during the forecast period, according to Technavio.
  • However, factors such as the Cost-effectiveness of conventional plastic over bioplastics may impede market growth.
  • View FREE PDF Sample Report
    The biopolymers and bioplastic market is estimated to grow at a CAGR of 14.36% between 2022 and 2027.

SIOS DataKeeper Cluster Edition Provides High Availability Protection for MailHippo Encryption Application on SQL Server

Retrieved on: 
Wednesday, October 4, 2023
Accountability Act, SIOS Technology Corp., Health Insurance Portability and Accountability Act, Failure, SQL, HA, RPO, SIOS, Confidentiality, Organization, SQL Server, Disaster, Risk, Microsoft Cluster Server, WSFC, HIPAA, Software, Cryptocurrency, Computer data storage, SAN

The company needed a robust high availability and disaster recovery (HA/DR) solution to protect the SQL Server database that their mission-critical applications run on.

Key Points: 
  • The company needed a robust high availability and disaster recovery (HA/DR) solution to protect the SQL Server database that their mission-critical applications run on.
  • “We needed an affordable, reliable solution that would allow us to use SQL Server Standard Edition,” said Almond.
  • “We used WSFC to create the clusters for our SQL Server environment just like a traditional cluster, and we simply added SIOS DataKeeper Cluster Edition.
  • MailHippo has been using SIOS SANless clusters and achieving high availability and disaster protection.

New Study Shows Longhorn Vaccines and Diagnostics’ Universal Influenza Vaccine, LHNVD-105, Generates Broad and Durable Immune Responses in Animal Models

Retrieved on: 
Wednesday, September 27, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Human, Army, Poultry, Comparable, Neuraminidase, Public, HA, NA, Immunity, ID, MD, Epitope, Mouse, Poster, Pig, Virus, Peptide, Vaccine, Longhorn

The study demonstrated that LHNVD-105 generates broad and durable immune responses in mice for several human, avian and swine influenza viruses.

Key Points: 
  • The study demonstrated that LHNVD-105 generates broad and durable immune responses in mice for several human, avian and swine influenza viruses.
  • “The Vaccines study extends these findings to show that the durability of the immune response and breadth of influenza strains the vaccines covers to include human and avian viruses.
  • LHNVD-105 demonstrated broad and durable immune responses to the vaccine peptide epitopes and multiple subtypes of influenza viruses.
  • LHNVD-105 induced durable immunity across human, swine, and avian influenza viruses, including A/H5N1, neutralizing both seasonal and pandemic strains.

Bloomage Biotech's Advanced 3D Skin Model Validates Hybloom™ Minitrue's Pivotal Role in Augmenting HA, Ceramides, and Collagen Production

Retrieved on: 
Wednesday, September 20, 2023
Elasticity, Collagen, Dermis, Ministries in Nineteen Eighty-Four, HA, 3D, Lipid, Nutrient, Hyaluronic acid, Research, Fibroblast, HA6, HA2, Blood, Oligosaccharide, Engineering, Ceramide, Lymphocyte, Transport, Health, Atomic mass, HA4, Skin, Skin test, Dietary supplement, Tanning (leather)

Bloomage Biotech's innovation has pioneered the reconstitution of a 3D full-layer skin model using human skin cells, applying principles of cellular biology and engineering, meticulously emulating human skin’s tissue structure.

Key Points: 
  • Bloomage Biotech's innovation has pioneered the reconstitution of a 3D full-layer skin model using human skin cells, applying principles of cellular biology and engineering, meticulously emulating human skin’s tissue structure.
  • Experiments utilizing the 3D full-layer skin model have verified that Hybloom™ Minitrue can be transdermally absorbed and act upon the dermis.
  • Through elevating endogenous HA, ceramides, and collagen levels, Hybloom™ Minitrue enhances skin hydration, elasticity, and resilience, giving the skin with a refined, silky-smooth texture, preserving its youthful luster.
  • Looking forward, with technological advancements and in-depth biologically active substance research, Bloomage Biotech aspires to proffer a diverse array of solutions to sustain skin health.

Realeve Unveils Breakthrough Solution to Treat Central Nervous System Disorders Including Stroke and Cluster Headache; Bypasses Brain’s Natural Barrier to Deliver Therapeutics

Retrieved on: 
Thursday, September 21, 2023
Research, Other Health, Hardware, Pharmaceutical, Oncology, Technology, Medical Devices, Science, Neurology, Biotechnology, FDA, Health, Other Science, Cleveland Clinic, Central nervous system, Alzheimer's disease, Neoplasm, HA, Stroke, CE marking, Post-stroke depression, Case Western Reserve University, Multimedia, Cluster headache, Brain damage, Brain, CNS, DSM-IV codes, SPG, System, BBB, Patient, Myenteric plexus, Autonomic nervous system, Blood–brain barrier, Cleveland, Pulsant, Medical device, Dentistry, Dermatology

Realeve has also been granted Breakthrough Device designation from the FDA with a goal of obtaining FDA approval and CE Mark to treat cluster headaches in 2024.

Key Points: 
  • Realeve has also been granted Breakthrough Device designation from the FDA with a goal of obtaining FDA approval and CE Mark to treat cluster headaches in 2024.
  • We are also exploring its applications in other central nervous system disease conditions and excited about the potential,” states Dr. Peter Bonutti, founder and president, Realeve.
  • This technology holds promise for addressing conditions like Alzheimer's, tumors, and other central nervous system disorders.
  • The targeted therapy provides both pain relief, and can increase blood flow and medication delivery to the central nervous system.

Lassen Therapeutics Presents New Data on LASN01 for the Treatment of Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease at the European Respiratory Society (ERS) and European Thyroid Association (ETA) Annual Meetings

Retrieved on: 
Monday, September 11, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, Oncology, Health, Clinical Trials, Well, STAT3, Therapy, Phosphorylation, Half-life, HA, Cancer, Cell proliferation, MBA, Doctor of Philosophy, ERS, Graves' ophthalmopathy, ETA, Teprotumumab, Patient, European Respiratory Society, Extracellular matrix, IPF, International Congress on Tuberculosis, Idiopathic pulmonary fibrosis, VI, TED, Pharmaceutical industry, Vaccine, Lassen

“Toward that, we have made significant progress in generating data with LASN01 in both clinical and nonclinical settings.

Key Points: 
  • “Toward that, we have made significant progress in generating data with LASN01 in both clinical and nonclinical settings.
  • We have completed our Phase 1 single ascending and multiple ascending dose cohorts and presented data from our healthy volunteer study at ERS.
  • We also presented our preclinical data in a TED fibro-inflammatory disease model using orbital fibroblasts (OF) at ETA.
  • Furthermore, LASN01 worked effectively in combination with teprotumumab, an approved agent for the treatment of TED, in inhibiting HA release.

Scottsdale's Aesthetic IQ Clinic Offers Breakthrough Undereye Treatment, Restylane® Eyelight

Retrieved on: 
Wednesday, September 13, 2023
Fatigue, HA, Ageing, Tenderness, Social media, MS, Pain, Itch, Bruise, Patient, Swelling, Restylane, Aesthetics, RN, Hallow, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Red, Food, Pharmaceutical industry, Nursing, CANS, Galderma

SCOTTSDALE, Ariz., Sept. 13, 2023 /PRNewswire-PRWeb/ -- Aesthetic IQ Clinic now offers Galderma's newest hyaluronic acid filler that was recently approved by the U.S. Food and Drug Administration (FDA) called Restylane® Eyelight. The undereye hyaluronic acid (HA) dermal filler, is the first and only product in the U.S. formulated with NASHA® Technology for volume loss, giving patients natural-looking results to treat undereye hallows, also known as shadows in adults over the age of 21.

Key Points: 
  • SCOTTSDALE, Ariz., Sept. 13, 2023 /PRNewswire-PRWeb/ -- Aesthetic IQ Clinic now offers Galderma's newest hyaluronic acid filler that was recently approved by the U.S. Food and Drug Administration (FDA) called Restylane® Eyelight.
  • "This exciting new treatment is formulated with NASHA Technology which means the filler is close to the body's natural hyaluronic acid," said Marissa Abdo, MS, RN, CANS, owner of Scottsdale-based Aesthetic IQ Clinic.
  • In a study, 87% of patients had reduced undereye hollowness at 3 months and Restylane Eyelight was found to be well tolerated under the eyes.
  • Aesthetic IQ Clinic is located at 7054 E Cochise Rd.

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™

Retrieved on: 
Tuesday, September 5, 2023
Surgeon, Nerve, Axogen, Reduction (orthopedic surgery), Doctor of Philosophy, Injury, HA, Patient, Environment, Logging, MD

ALACHUA, Fla. and TAMPA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the full launch of Axoguard HA+ Nerve Protector.

Key Points: 
  • ALACHUA, Fla. and TAMPA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the full launch of Axoguard HA+ Nerve Protector.
  • “Axoguard HA+ is an important extension of our nerve protection platform,” commented Karen Zaderej, Axogen's Chairman, CEO, and President.
  • “The release of Axoguard HA+ expands opportunities for surgeons to treat a wider range of nerve protection challenges.”
    Axoguard HA+ Nerve Protector is a proprietary nerve protection device uniquely designed to provide both short- and long-term protection for peripheral nerve injuries.
  • The nerve protection category covers a wide range of injuries and defects, including nerve compression, crush, and complex traumatic injuries.